1
|
Goes LR, Siqueira JD, Garrido MM, Alves BM, Pereira ACPM, Cicala C, Arthos J, Viola JPB, Soares MA. New infections by SARS-CoV-2 variants of concern after natural infections and post-vaccination in Rio de Janeiro, Brazil. Infect Genet Evol 2021; 94:104998. [PMID: 34252616 PMCID: PMC8270730 DOI: 10.1016/j.meegid.2021.104998] [Citation(s) in RCA: 15] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 05/10/2021] [Revised: 06/07/2021] [Accepted: 07/07/2021] [Indexed: 12/28/2022]
Abstract
After a one-year rollout of the pandemic caused by SARS-CoV-2, the continuous dissemination of the virus has generated a number of variants with increased transmissibility and infectivity, called variants of concern (VOC), which now predominate worldwide. Concerns about the susceptibility of humans that have already been infected before or those already vaccinated to infection by VOC rise among scientists and clinicians. Herein, we assessed the prevalence of different VOC among recent infections at the Brazilian National Cancer Institute (Rio de Janeiro, Brazil). By using a Sanger-based sequencing approach targeting the viral S gene to identify VOC, we have analyzed 72 recent infections. The overall prevalence of VOC was 97%. Among the subjects analyzed, six had been vaccinated with the ChAdOx1-S/nCoV-19 (n = 4; one with two doses and three with one dose) or the CoronaVac (n = 2; both with 2 doses) vaccine, while five subjects represented reinfection cases, being two of them also part of the vaccinated group (each one with one vaccine type). All vaccinated and re-infected subjects carried VOC irrespective of the vaccine type taken, the number of doses taken, IgG titers or being previously infected during the first wave of the Brazilian pandemic. Importantly, all six vaccinees only had mild symptoms. We present here several examples of how natural infections or vaccination may not be fully capable of conferring sterilizing immunity against VOC.
Collapse
Affiliation(s)
- Livia R Goes
- Oncovirology Program, Brazilian National Cancer Institute, Rua Andre Cavalcanti, 37, Rio de Janeiro, RJ 20231-050, Brazil; Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, Building 10 Room 6A08, 9000 Rockville Pike, Bethesda, MD 20892, USA.
| | - Juliana D Siqueira
- Oncovirology Program, Brazilian National Cancer Institute, Rua Andre Cavalcanti, 37, Rio de Janeiro, RJ 20231-050, Brazil.
| | - Marianne M Garrido
- Hospital Infection Control Committee, Brazilian National Cancer Institute, Praça Cruz Vermelha, 23, Rio de Janeiro, RJ 20230-130, Brazil.
| | - Brunna M Alves
- Oncovirology Program, Brazilian National Cancer Institute, Rua Andre Cavalcanti, 37, Rio de Janeiro, RJ 20231-050, Brazil.
| | - Ana Cristina P M Pereira
- Section of Anesthesiology, Brazilian National Cancer Institute, Praça Cruz Vermelha, 23, Rio de Janeiro, RJ 20230-130, Brazil.
| | - Claudia Cicala
- Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, Building 10 Room 6A08, 9000 Rockville Pike, Bethesda, MD 20892, USA.
| | - James Arthos
- Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, Building 10 Room 6A08, 9000 Rockville Pike, Bethesda, MD 20892, USA.
| | - João P B Viola
- Program of Immunology and Tumor Biology, Brazilian National Cancer Institute, Rua Andre Cavalcanti, 37, Rio de Janeiro, RJ 20231-050, Brazil.
| | - Marcelo A Soares
- Oncovirology Program, Brazilian National Cancer Institute, Rua Andre Cavalcanti, 37, Rio de Janeiro, RJ 20231-050, Brazil; Department of Genetics, Federal University of Rio de Janeiro, Av. Carlos Chagas Filho, 373, Rio de Janeiro, RJ 21941-590, Brazil.
| |
Collapse
|